Navigation Links
ZyGEM Appoints Leading Biotechnology Expert to Head Clinical Advisory Board
Date:2/14/2008

--Dr. Mark Ahn Brings ZyGEM Extensive Expertise in Developing and

Commercializing Novel Clinical Products--

SOLANA BEACH, Calif., Feb. 14 /PRNewswire/ -- ZyGEM Corp. Ltd., a leading provider of unique and innovative enzymatic solutions for DNA extraction and detection and other life sciences applications, today announced the appointment of Mark J. Ahn, Ph.D., as Chair of its newly formed Clinical Advisory Board. Dr. Ahn and the new advisory board will assist ZyGEM on expanding its established and new technology platforms into additional clinical medicine applications, with a focus on molecular diagnostics. Dr. Ahn is Professor and Chair, Science & Technology Entrepreneurship at Victoria University of Wellington in New Zealand. Previously, he was President and CEO of Hana Biosciences, Inc. and Vice President of Hematology at Genentech, Inc.

"Mark's expert understanding of drug discovery, development and commercialization will be invaluable as we expand our existing and new technologies into clinical medicine applications," said Paul Kinnon, president and CEO of ZyGEM. "Mark played a key role in helping to build Genentech's oncology business into a world leader before becoming founding CEO of an entrepreneurial cancer firm. His life sciences industry experience spans multiple markets, including health providers, major biopharmaceutical firms, entrepreneurial companies and academia-all potentially important customer segments for ZyGEM's growing product lines. We are delighted to have him on board."

ZyGEM currently develops and markets innovative solutions for life sciences applications that leverage the properties of unique enzymes in the company's extensive proprietary culture collection. Its products include innovative DNA extraction and detection solutions for forensics, livestock and agriculture, basic research and clinical applications. ZyGEM's technology is based on more than two decades of research and development on the company's exclusive collection of microorganisms and fungi isolated from extreme environments. ZyGEM is also developing several new and complementary technology platforms.

"I am delighted to join the ZyGEM team at such an exciting time in the company's development," said Dr. Ahn. "I look forward to supporting ZyGEM's efforts as it expands its enzyme-based solutions and other novel technologies into new market segments that will bring the benefits of its innovative approaches more directly to physicians and patients."

Dr. Ahn is Professor and Chair, Science & Technology Entrepreneurship with a joint appointment from the faculties of Commerce & Administration and Science at Victoria University of Wellington. Prior to joining the university, Dr. Ahn was founder, President, and Chief Executive Officer of Hana Biosciences. Prior to Hana, he served as Vice President, Hematology and corporate officer at Genentech. Previously, he held a series of positions of increasing responsibility at Amgen and Bristol-Myers Squibb. Dr. Ahn also serves on the Boards of Directors of RXi Pharmaceuticals and Access Pharmaceuticals. He received B.A. and M.B.A. degrees from Chaminade University of Honolulu and holds a Ph.D. from the University of South Australia.

About ZyGEM

ZyGEM Corporation Limited is a rapidly growing biotechnology company with a range of innovative enzyme-based products and technologies based on the company's exclusive collection of microorganisms from extreme environments. ZyGEM's technology has significant competitive advantages over existing methods and has potential applications in a number of sizeable global markets. ZyGEM currently produces DNA extraction and detection products, molecular biology enzymes and individual enzymes and diagnostics, serving life sciences customers in basic research, forensics, clinical diagnostics and agriculture. ZyGEM has facilities in New Zealand and the U.S. For more information, visit http://www.ZyGEM.com.

Contacts:

Corporate: Media:

Paul Kinnon GendeLLindheim BioCom Partners

President and CEO Barbara Lindheim

858 720-8333 212 918-4650


'/>"/>
SOURCE ZyGEM Corp. Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Laureate Pharma Appoints Gary Swan as Vice President of Operations
2. Immtech Appoints Blythe Weigh as Strategic Advisor
3. PeriCor Therapeutics Appoints K. Tucker Andersen to Board of Directors
4. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
5. Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.
6. Cepheid Appoints Senior VP, Chief Financial Officer to Management Team
7. Anesiva Appoints Daniel Janney to Board of Directors
8. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
9. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
10. Transgenomic Appoints David Pauluzzi to Board of Directors
11. China Pharma Appoints Three Independent Non-Executive Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving Tree Wellness Center ... the needs of consumers who are incorporating medical marijuana into their wellness and ... , As operators of two successful Valley dispensaries, The Giving Tree’s two founders, ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... advanced instruments and applications consulting for microscopy and surface analysis, Nanoscience Instruments ... consulting, Nanoscience Analytical offers a broad range of contract analysis services for ...
(Date:10/7/2017)... Oct. 6, 2017  The 2017 Nobel Prize ... scientists, Jacques Dubochet, Joachim Frank and ... cryo-electron microscopy (cryo-EM) have helped to ... structural biology community. The winners worked with systems ... routinely produce highly resolved, three-dimensional images of protein ...
(Date:10/6/2017)... ... October 06, 2017 , ... On Tuesday, October 24th, ABC² ... the first-ever adaptive clinical trial for glioblastoma (GBM). The featured speaker will be ... and open to the public, but registration is required. , WHAT: ABC² ...
Breaking Biology Technology:
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. ... company, announces the filing of its 2016 Annual Report on Form ... Exchange Commission. ... Form 10-K is available in the Investor Relations section of the ... on the SEC,s website at http://www.sec.gov . 2016 ...
(Date:4/13/2017)... PUNE, India , April 13, 2017 According ... Identity Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication ... by MarketsandMarkets™, the IAM Market is expected to grow from USD 14.30 ... Annual Growth Rate (CAGR) of 17.3%. ... ...
(Date:4/11/2017)... , Apr. 11, 2017 Research and Markets ... 2017-2021" report to their offering. ... The global eye tracking market to grow at a CAGR ... Global Eye Tracking Market 2017-2021, has been prepared based on an ... the market landscape and its growth prospects over the coming years. ...
Breaking Biology News(10 mins):